Healthcare & Insurance
Aino Health AB (publ): Aino Health sells ownership in the Finnish occupational health provider Maresan
Aino Health (Aino) announces today that they have sold their shares in the Finnish occupational provider Maresan. Aino’s ownership in Maresan constitutes around 16%, which corresponds to a cash purchase price of approximately 2 million SEK. As Aino earlier has depreciated the
Tuesday, December 10, 2019
Philips and Regional Medical Center announce USD 16 million, long-term strategic partnership to innovate patient care for residents of rural South
December 10, 2019 Partnership gives community health system access to same innovative Philips diagnostic imaging solutions of larger networks, bringing quality care closer to home and delivering on the Quadruple Aim Amsterdam, the Netherlands and Orangeburg, United States –
Tuesday, December 10, 2019
Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases
Targeting mid-year 2020 to commence clinical trials of Brilacidin for UP/UPS indicationRegulatory documents submitted to health authorities for planned Ulcerative Colitis study BEVERLY, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a
Tuesday, December 10, 2019
TOMI Environmental Solutions, Inc. Implements SteraMist into Multiple Compounding Pharmacies
BEVERLY HILLS, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a
Tuesday, December 10, 2019
Generex Biotechnology Announces New Structure, Pay Date and Ex-Date for the Previously Postponed Shareholder Stock Dividend and Declares a New Share
Generex will give a 2 to 5 stock dividend to shareholders paying 2 GNBT shares for every 5 shares heldShareholders to receive an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology sharesNew Dates Established for shareholder stock dividend New Pay Date: January 3, 2020New Ex-Date: January
Tuesday, December 10, 2019
Beyond Air Prices $10.5 Million Underwritten Offering of Common Stock and Concurrent Private Placement
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung
Tuesday, December 10, 2019
Nova Leap Health Corp. to Present at the 12th Annual LD Micro Main Event
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Dec. 10, 2019 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, is
Tuesday, December 10, 2019
Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020. Dr. Bodick co-founded Flexion in 2007 with Michael Clayman, M.D., the company’s President
Tuesday, December 10, 2019
Herantis Pharma Plc has submitted a listing application to Nasdaq Stockholm AB for the listing of the offer shares
Herantis Pharma Plc has submitted a listing application to Nasdaq Stockholm AB for the listing of the offer shares Herantis Pharma Plc Company release 10 December 2019 at 4:00 PM EET THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
Tuesday, December 10, 2019
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock
YONKERS, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten
Tuesday, December 10, 2019
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify their
Tuesday, December 10, 2019
Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass CytometrySOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today
Tuesday, December 10, 2019
Agritek Holdings, Inc. Announces Board Approval and Completion of Due Diligence Period to Proceed with Apex Extractions Acquisition Including Assets,
LOS ANGELES, CA, Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Agritek Holdings, Inc. (AGTK) www.AgritekHoldings.com, a fully integrated, active real estate investor for the cannabis sector and consultant for multiple cannabis brands, today announced that the Company has completed the
Tuesday, December 10, 2019
National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today
Tuesday, December 10, 2019
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced
Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone PainNEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer
Tuesday, December 10, 2019
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s diseaseROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage
Tuesday, December 10, 2019
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors
DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today the appointment of Mark McCamish, MD, Ph.D. to its board of
Tuesday, December 10, 2019
Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at
Tuesday, December 10, 2019
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Day for
Tuesday, December 10, 2019
RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in
Tuesday, December 10, 2019
